HR for death or leukemic transformation in a multivariate model
| . | HR (95% CI) . | P . |
|---|---|---|
| Patients with CD34+cell samples (n = 100) | ||
| Death | ||
| Hemoglobin (g/dL) | 0.54 (0.37-0.77) | <.001 |
| Bone marrow blast (%) | 1.05 (1.02-1.09) | .003 |
| Age (y) | 1.09 (1.02-1.16) | .009 |
| IMP vs EMK subgroup | 4.87 (1.25-19.0) | .02 |
| Leukemic transformation* | ||
| Patients with only BMMNC samples (n = 114) | ||
| Death | ||
| Bone marrow blast (%) | 1.11 (1.06-1.16) | <.001 |
| Hemoglobin (g/dL) | 0.67 (0.52-0.86) | .001 |
| IMP vs EMK subgroup | 2.90 (1.10-7.62) | .03 |
| Absolute neutrophil count (×109/L) | 1.12 (1.00-1.26) | .05 |
| Cytogenetic abnormalities | 2.16 (0.92-5.07) | .08 |
| Platelet (×109/L) | 0.996 (0.992-1.001) | .12 |
| Leukemic transformation | ||
| Bone marrow blast (%) | 1.14 (1.08-1.21) | <.001 |
| IMP vs EMK subgroup | 5.86 (1.59-21.6) | .008 |
| Hemoglobin (g/dL) | 0.80 (0.66-0.98) | .03 |
| . | HR (95% CI) . | P . |
|---|---|---|
| Patients with CD34+cell samples (n = 100) | ||
| Death | ||
| Hemoglobin (g/dL) | 0.54 (0.37-0.77) | <.001 |
| Bone marrow blast (%) | 1.05 (1.02-1.09) | .003 |
| Age (y) | 1.09 (1.02-1.16) | .009 |
| IMP vs EMK subgroup | 4.87 (1.25-19.0) | .02 |
| Leukemic transformation* | ||
| Patients with only BMMNC samples (n = 114) | ||
| Death | ||
| Bone marrow blast (%) | 1.11 (1.06-1.16) | <.001 |
| Hemoglobin (g/dL) | 0.67 (0.52-0.86) | .001 |
| IMP vs EMK subgroup | 2.90 (1.10-7.62) | .03 |
| Absolute neutrophil count (×109/L) | 1.12 (1.00-1.26) | .05 |
| Cytogenetic abnormalities | 2.16 (0.92-5.07) | .08 |
| Platelet (×109/L) | 0.996 (0.992-1.001) | .12 |
| Leukemic transformation | ||
| Bone marrow blast (%) | 1.14 (1.08-1.21) | <.001 |
| IMP vs EMK subgroup | 5.86 (1.59-21.6) | .008 |
| Hemoglobin (g/dL) | 0.80 (0.66-0.98) | .03 |
Failure in convergence due to no leukemic transformation in the EMK subgroup.